Top Story

Targeted treatments for lung cancer likely to drive field forward

October 17, 2014

WASHINGTON — Recent progress in the use of genomics to treat lung cancer is likely to advance the field of cancer treatment, according to Mark G. Kris, MD, the Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center.

“It’s not one-size fits all anymore,” Kris said during his presentation at the U.S. News & World Report’s Hospital of Tomorrow Forum. “The difference is, we now have a better knowledge of biology, and an ability to test for these concepts that we’ve discovered; and we have these targeted therapies.”

In the Journals

Medicare reimbursement policy failed to significantly reduce chemotherapy cost

October 16, 2014
The Medicare Prescription Drug, Improvement and Modernization Act of 2003, intended to slow the skyrocketing costs of drugs the federal government must pay for to treat…
Meeting News CoveragePerspective

Physician tumor board participation linked to clinical trial enrollment

October 14, 2014
Patients with lung or colorectal cancers whose physicians attended weekly multidisciplinary tumor board meetings were more likely to enroll in clinical trials, according…
In the Journals

ASCO: Offer EGFR, ALK testing to all patients with lung adenocarcinoma

October 13, 2014
ASCO today endorsed a joint clinical practice guideline from three other entities that addresses questions about the appropriate use of EGFR-mutation and…
CME
figure

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

figure Meeting News Coverage

Targeted treatments for lung cancer likely to drive field forward

October 17, 2014
WASHINGTON — Recent progress in the use of genomics to treat lung cancer is likely to advance the field of cancer treatment, according to…
In the Journals

Medicare reimbursement policy failed to significantly reduce chemotherapy cost

October 16, 2014
The Medicare Prescription Drug, Improvement and Modernization Act of 2003, intended to slow the skyrocketing costs of drugs the federal government…
Meeting News Coverage Perspective

Physician tumor board participation linked to clinical trial enrollment

October 14, 2014
Patients with lung or colorectal cancers whose physicians attended weekly multidisciplinary tumor board meetings were more likely to enroll in…
In the Journals

ASCO: Offer EGFR, ALK testing to all patients with lung adenocarcinoma

October 13, 2014
ASCO today endorsed a joint clinical practice guideline from three other entities that addresses questions about the appropriate use of…
In the Journals

E-cigarettes unhelpful for smoking cessation among patients with cancer

October 13, 2014
A study of patients with cancer who smoke showed those who used electronic cigarettes were more nicotine-dependent than nonusers.Those who used…
Institution Notes

UPCI appoints co-director of lung cancer program

October 12, 2014
James Herman, MD, has been named co-leader of the University of Pittsburgh Cancer Institute’s lung cancer program.Herman, a leader in the…
Institution Notes

Meridian appoints medical director for thoracic oncology

October 7, 2014
Meridian Cancer Care appointed Thomas Lee Bauer II, MD, as its medical director for thoracic oncology.Bauer will be based at Jersey Shore University…
figure In the Journals

Two novel mutations linked to ALK inhibitor resistance in NSCLC

October 7, 2014
Two novel ALK mutations, V1180L and I1171T, were associated with resistance to crizotinib and alectinib but were sensitive to other next-generation…
In the Journals

Addition of bevacizumab to erlotinib improved outcomes in EGFR-mutant NSCLC

October 6, 2014
Patients with EGFR-mutant non–small cell lung cancer who underwent treatment with bevacizumab plus erlotinib demonstrated longer PFS than those…
FDA News

FDA grants ‘breakthrough’ designation for ALK-positive NSCLC therapy

October 2, 2014
The FDA granted breakthrough therapy designation for an investigational treatment for patients with anaplastic lymphoma kinase-positive metastatic…
More Headlines »